The immune cytokine interleukin (IL)-7 and the β-chain of hepatocyte growth factor (HGF) aggregate to form a naturally occurring heterodimer that stimulates the growth of common Research.
Introduction
than 3 months before use in the experiments. ATCC characterized cells by using karyotyping and cytochrome C oxidase I testing. BALB/c, C57BL/6 and congenitally athymic nude mice were purchased from Harlan Sprague-Dawley (Indianapolis, IN) and the National Cancer Institute (Frederick, MD). Mice were housed, treated, and handled in accordance with the guidelines set forth by the University of Connecticut Health Center Animal Care Committee. rIL-7 was purchased from PreproTech (Rocky Hill, NJ), eBiosciences (San Diego, CA) and R&D systems (Minneapolis, MN). rHGFβ and rIL-7/HGFβ was cloned, expressed, and purified as we have described (3, 4) .
Evaluation of local tumor growth and pulmonary metastasis
Cancer cells in the exponential growth phase were harvested and washed in PBS before in vivo injection. To induce localized tumors, 2x10 
Evaluation of TILs and DCs
At the indicated time points, the s.c. tumors were excised, weighed, minced into small fragments, and digested in 1 mg/ml collagenase IV (Sigma, St. Louis, MO) and 0.1 mg/ml DNase (Sigma, St. Louis, MO) at 37 0 C for 1 hour. The dissociated cells were then prepared for phenotypic analysis of T cells and DCs by flow immunocytometry.
Flow immunocytometry
Single-cell suspensions from tumors and draining or non-draining lymph nodes were stained with the following fluorochrome-conjugated antibodies: CD4, CD8, CD11c, CD80, CD86, CD3 and DX5 (BioLegend or BD Biosciences, San Diego, CA). The samples were analyzed on a FACSCalibur flow cytometer (Becton and Dickinson). Data analysis was done using FlowJo software (Ashland, OR).
ELISPOT assay
ELISPOT assay measuring IFN-γ were used to assess the in vitro T cell responses to stimulation with CT-26 or B16F10 cells. Splenocytes, containing 1x10 5 T cells/well, and irradiated cancer cells (1x10
Results

rIL-7/HGFβ treatment inhibits local tumor growth
To determine whether rIL-7/HGFβ has antitumor activity, murine CT-26 colon cancer cells were injected s.c. into syngeneic BALB/c mice and, at 2-day intervals from days 2-24, the mice were injected at the tumor site with different doses of rIL-7/HGFβ (2.5, 5, 15 and 30 μg/injection) or control vehicle (PBS). As shown in Figure 1A , tumor growth was inhibited in a dose-responsive manner, with no detectable effect seen by day 30 at the 2.5µg level and >80% inhibition occurring at the 30μg level. To compare the antitumor effect of rIL-7/HGFβ with its component cytokines, BALB/c mice were injected at the tumor site with optimal and equimolar amounts of rIL-7/HGFβ (15 μg/injection), rIL-7 (5 μg/injection) and/or rHGFβ (10 μg/injection), according to the above schedule. As shown in Figure 1B , rIL-7 alone or mixed with rHGFβ inhibited local tumor growth by ~30% by day 30, whereas rHGFβ alone had no effect. In contrast, the rIL-7/HGFβ hybrid cytokine inhibited tumor cell growth by ~76% (p<0.01). As shown in
Research. Figure 1C , the ability of rIL-7/HGFβ to inhibit local tumor growth was not restricted to colon cancer, but applied to malignant melanoma as well. Furthermore, as shown in Figure 1D , significant antitumor activity was observed in mice in which rIL-7/HGFβ treatment was initiated 10 days after melanomas had been established.
To determine whether rIL-7/HGFβ, rIL-7 and/or HGFβ directly affect the growth of 
rIL-7/HGFβ induces significant infiltration of DCs and T cells into the tumors
The presence of large proportions of TILs has been associated with favorable clinical outcomes in cancer patients (13, 15) . We therefore determined whether rIL-7/HGFβ, rIL- 
rIL-7/HGFβ-treatment induces a tumor-specific immunological response
The above results suggest that the mechanism by which rIL-7/HGF inhibits local tumor To confirm that T cells were involved in the antitumor activity of rIL-7/HGFβ, the previous experiments were repeated in congenitally athymic (nude) mice. In contrast to its effects in euthymic mice, rIL-7/HGFβ failed to inhibit local tumor growth in nude mice by both CT-26 colon cancer cells ( Figure 6A ) and B16F10 melanoma cells ( Figure   6C ). In contrast, the antimetastatic activity of rIL-7/HGFβ was only partly lost in nude
Research. with NK cells to inhibit tumor cell growth and survival (20) (21) (22) . However, the results also suggest that an additional, T cell-independent mechanism, may also enable systemically administered rIL-7/HGFβ to inhibit the formation of metastases (as opposed to solid tumors), which continues to occur in nude mice.
Several studies have shown that IL-7 has antitumor activity (10-16). For example, tumor cell lines transfected with the IL-7 gene had reduced, T cell-dependent, tumorigenicity in vivo (10, 11). Similarly, the local or systemic administration of rIL-7 also had antitumor effects (12, 13) , especially when combined with cancer vaccines (15, 16) . Our data also
showed that rIL-7 could inhibit both tumor growth and the formation of metastases by CT-26 colon cancer cells. However, when given in the same molar amounts, our data show that rIL-7/HGFβ was significantly more effective than rIL-7 (and/or HGFβ) in inhibiting tumor formation. This difference may be qualitative as well as quantitative, as rIL-7/HGFβ was able to activate tumor-infiltrating DCs, whereas rIL-7 was not. This is 
